Affinity Asset Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Affinity Asset Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-372,476	Closed	-$790K	–	75
2022 Q3	$790K	Sell	372,476 -94,131	-20%	-$237K	0.22%	54
2022 Q2	$1.25M	Sell	466,607 -92,412	-17%	-$344K	0.53%	38
2022 Q1	$2.43M	Sell	559,019 -490,702	-47%	-$2.01M	0.39%	36
2021 Q4	$5.44M	Buy	1,049,721 +74,721	+8%	+$400K	1.97%	22
2021 Q3	$5.99M	Buy	975,000 +75,000	+8%	+$598K	1.51%	16
2021 Q2	$9.09M	Buy	900,000 +211,000	+31%	+$2.29M	3.25%	7
2021 Q1	$9.49M	Buy	689,000 +389,000	+130%	+$5.39M	3.22%	9
2020 Q4	$3.25M	Buy	+300,000	New	+$3.16M	1.73%	17

Other funds holding NAUT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

Affinity Asset Advisors's NAUT Position: Q4 2022 in Review

Affinity Asset Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 372,476 shares — an estimated $790K sold.

Affinity Asset Advisors first reported a position in NAUT in Q4 2020 and held it in 8 quarters. The position peaked at $9.49M in Q1 2021. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

Affinity Asset Advisors reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
Affinity Asset Advisors sold 372,476 Nautilus Biotechnolgy shares in Q4 2022, an estimated $790K.
Affinity Asset Advisors first reported a position in Nautilus Biotechnolgy in Q4 2020 and held it in 8 quarters.
Affinity Asset Advisors's Nautilus Biotechnolgy position peaked at $9.49M in Q1 2021.
81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.